| Insulins

Variability of 501 Inhaled Insulin Absorption and Action

book_2 Source: ADA 2020 - Poster session
calendar_today Published on Medfyle: July 2020
headphones 4 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Novel 501 insulin is a liquid formulation of human insulin for inhalation.
  • Its glucodynamic properties make 501 insulin a promising candidate for a needle-free mealtime insulin.
  • The intra-individual response to self-administration of 501 inhaled insulin is as reproducible as that of s.c. insulin lispro injected by experienced staff.
  • This is a clinically meaningful outcome and enables individual dose titration of 501 insulin in future treatment.
Presenting Author
Read more arrow_downward Hide arrow_upward


Eric Zijlstra, PhD
Profil, Neuss, Germany


With a background in Biomedical Engineering (Eindhoven University of Technology, The Netherlands),  Dr. Eric Zijlstra started his career in the field of diabetes as a postgraduate researcher at the University of Birmingham (UK) in collaboration with AstraZeneca (Alderley Park, UK). In 2008 Eric joined Profil and has since worked on more than 80 clinical trials, investigating a large variety of diabetes drugs and medical devices in development. On the drug side, his main interest lies with novel insulin formulations, from faster-acting to ultra long-acting and their oral, inhaled and intradermal administrations. On the device side, blood glucose monitoring and insulin application devices are of special interest.

Eric is currently a research scientist and expert in the field of diabetes technology, alternative route administrations of insulin and glucose clamp studies. In his current role as Executive Director Project Development at Profil he leads a team of scientific consultants, oversees clinical trial design preparations and supports the dissemination of trial results at international diabetes conferences and scientific journals.

Read more arrow_downward Hide arrow_upward

Dr. Zijlstra is an employee of Profil, the research site where the study was conducted.

Dr. Zijlstra has received speaker honoraria and/or travel grants from Eli Lilly, Novo Nordisk and Roche Diabetes Care.